NCT03820817View on ClinicalTrials.gov

Rifaximin in Patients With Monoclonal Gammopathy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
IgA Monoclonal GammopathyIgG Monoclonal GammopathyIgM Monoclonal GammopathyLight Chain Deposition DiseaseMonoclonal GammopathySmoldering Waldenstrom MacroglobulinemiaWaldenstrom MacroglobulinemiaGammopathy, MonoclonalGammopathy Igg
Interventions
DRUG

Rifaximin

Given PO

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER